Microneedle Systems for Vaccine Delivery: the story so far

Hossain, Kamal; Ahmed, Taksim; Bhusal, Prabhat; Subedi, Robhash Kusam; Salahshoori, Iman; Soltani, M.; Hassanzadeganroudsari, Majid

doi:10.1080/14760584.2020.1874928

Cited by 31 publications

(31 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 New technologies are being developed for vaccination against infectious diseases by exploring the capacities of the skin immune system, such as microneedle array patch (MAP), high-density MAP or new skin-targeted drug delivery strategies, and several works have shown encouraging results. 38,39 Use of dissolvable microneedle patches for influenza vaccination was well-tolerated and generated robust antibody responses, 40 and even a dose reduction (2.5 μg dose -1/6 of the standard dose) would seem to induce an immunization similar to full dose of 15 μg injected IM. 41 A recent work encourage the improved of MAP delivery strategies for vaccination because of the advantages of less pain, self-administration, improved stability, convenience, and safety.…”

Section: Evidence From the Literaturementioning

confidence: 99%

See 1 more Smart Citation

Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?

Migliore¹,

Gigliucci²,

Marzo³

et al. 2021

RMHP

View full text Add to dashboard Cite

This narrative review is the final output of an initiative of the SIM (Italian Society of Mesotherapy). A narrative review of scientific literature on the efficacy of fractional intradermal vaccination in comparison with full doses has been conducted for the following pathogens: influenza virus, rabies virus, poliovirus (PV), hepatitis B virus (HBV), hepatitis A virus (HAV), diphtheria-tetanus-pertussis bacterias (DTP), human papillomavirus (HPV), Japanese encephalitis virus (JE), meningococcus, varicella zoster virus (VZV) and yellow fever virus. The findings suggest that the use of the intradermal route represents a valid strategy in terms of efficacy and efficiency for influenza, rabies and HBV vaccines. Some systematic reviews on influenza vaccines suggest the absence of a substantial difference between immunogenicity induced by a fractional ID dose of up to 20% and the IM dose in healthy adults, elderly, immunocompromised patients and children. Clinical studies of remaining vaccines against other pathogens (HAV, DTP bacterias, JE, meningococcal disease, VZV, and yellow fever virus) are scarce, but promising. In the context of a COVID-19 vaccine shortage, countries should investigate if a fractional dosing scheme may help to save doses and achieve herd immunity quickly. SIM urges the scientific community and health authorities to investigate the potentiality of fractionate intradermal administration in anti-COVID-19 vaccination.

show abstract

Section: Evidence From the Literaturementioning

confidence: 99%

“…New technologies are being developed for vaccination against infectious diseases by exploring the capacities of the skin immune system, such as microneedle array patch (MAP), high-density MAP or new skin-targeted drug delivery strategies, and several works have shown encouraging results. 38 , 39 …”

Section: Evidence From the Literaturementioning

confidence: 99%

Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?

Migliore¹,

Gigliucci²,

Marzo³

et al. 2021

RMHP

View full text Add to dashboard Cite

show abstract

“…MNs can promote the deposition of the vaccines by creating micropores in the skin, facilitating vaccine transport, and hence reducing the necessary dose of antigens/ vaccines for the immunological responses. A significant number of MNs mediated vaccine candidates have shown encouraging results in preclinical and clinical trials (Hossain et al, 2020).…”

Section: Microneedlesmentioning

confidence: 99%

Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines

et al. 2021

View full text Add to dashboard Cite

Cancer vaccines represent among the most promising strategies in the battle against cancers. However, the clinical efficacy of current cancer vaccines is largely limited by the lack of optimized delivery systems to generate strong and persistent antitumor immune responses. Moreover, most cancer vaccines require multiple injections to boost the immune responses, leading to poor patient compliance. Controlled-release drug delivery systems are able to address these issues by presenting drugs in a controlled spatiotemporal manner, which allows co-delivery of multiple drugs, reduction of dosing frequency and avoidance of significant systemic toxicities. In this review, we outline the recent progress in cancer vaccines including subunit vaccines, genetic vaccines, dendritic cell-based vaccines, tumor cell-based vaccines and in situ vaccines. Furthermore, we highlight the efforts and challenges of controlled or sustained release drug delivery systems (e.g., microparticles, scaffolds, injectable gels, and microneedles) in ameliorating the safety, effectiveness and operability of cancer vaccines. Finally, we briefly discuss the correlations of vaccine release kinetics and the immune responses to enlighten the rational design of the next-generation platforms for cancer therapy.

show abstract

“…Vaccines are biological formulations containing live or attenuated antigen that elicit an immune response, confer long-lasting immunity, and serve an essential role in reducing morbidity and mortality for numerous infectious diseases. 1 In 2020 alone, over 124 million cases of COVID-19 were diagnosed as part of the worldwide pandemic and over 2.74 million individuals lost their lives to the disease globally, 2 spurring prophylactic vaccine development and delivery into a global health priority. As of March 2021, 3 vaccines had been approved by the US Food and Drug Administration, an additional 289 experimental COVID-19 vaccines were in development, 66 were in clinical testing, and 5 had been authorized by regulatory authorities or the World Health Organization (WHO) internationally.…”

Section: Introductionmentioning

confidence: 99%

“…Recent innovation efforts have investigated the potential for transdermal approaches such as microneedle (MN) patches as an alternative modality for painless drug delivery. 1 , 16 – 19 MN array technology utilizes multiple microscopic projections from a plate, which delivers a vaccine in the form of a patch placed on the skin; these patches allow for painless antigen delivery with potentially improved immune response due to their capacity for sustained release. Furthermore, MN patches deliver high concentrations of vaccine to the localized skin environment, which is rich in antigen-presenting cells and has the potential to elicit a dose-sparing effect that enables single-dose vaccine delivery.…”

Section: Introductionmentioning

confidence: 99%

Transdermal approaches to vaccinations in the COVID-19 pandemic era

Lee

Pan

Nambudiri

2021

Therapeutic Advances in Vaccines and Immunotherapy

View full text Add to dashboard Cite

The COVID-19 pandemic has necessitated rapid vaccine development for the control of the disease. Most vaccinations, including those currently approved for COVID-19 are administered intramuscularly and subcutaneously using hypodermic needles. However, there are several disadvantages including pain and fear of needlesticks, the need for two doses, the need for trained health care professionals for vaccine administration, and barriers to global distribution given the need for cold supply chain. Recently, transdermal techniques have been under investigation for vaccines including COVID-19. Microneedle array technology utilizes multiple microscopic projections from a plate which delivers a vaccine in the form of a patch placed on the skin, allowing for painless antigen delivery with improved immune response. In this review, we discuss challenges of existing vaccines and review the literature on the science behind transdermal vaccines including microneedles, current evidence of application in infectious diseases including COVID-19, and considerations for implementation and global access.

show abstract

Microneedle Systems for Vaccine Delivery: the story so far

Cited by 31 publications

References 108 publications

Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?

Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?

Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines

Transdermal approaches to vaccinations in the COVID-19 pandemic era

Contact Info

Product

Resources

About